Phillip Brian Smith, MD

Dr. Smith completed his residency in pediatrics and a fellowship in neonatal medicine at Duke University Medical Center in 2004 and 2007, respectively. He completed an MHS in clinical research from Duke University in 2006 and an MPH in biostatistics from the University of North Carolina at Chapel Hill in 2009. He research is focused on pediatric drug safety, neonatal pharmacology, and the epidemiology of neonatal infections. He is the chief of the Division of Quantitative Sciences in the Department of Pediatrics at Duke University Medical Center. Dr. Smith is or has been the protocol chair for more than 10 studies of drugs in infants and children. He is the Principal Investigator for the Environmental Influences on Child Health Outcomes (ECHO) Coordinating Center.
Education and Training
- Fellowship in Neonatal-Perinatal Medicine, Pediatrics, Duke University, 2004 - 2007
- Pediatric Internship & Residency, Pediatrics, Duke University, 2001 - 2004
- M.P.H., University of North Carolina - Chapel Hill, 2009
- M.H.S., Duke University School of Medicine, 2006
- M.D., Mercer University, 2001
Selected Grants and Awards
- Unified Program for Therapeutics in Children
- ECHO Administrative Supplement - Neonatal Opioid Exposures
- ECHO Coordinating Center
- Duke KURe Program
- Duke CTSA (TL1)
- Duke Summer Training in Academic Research (Duke's STAR)
- Eunice Kennedy Shriver NICHD Cooperative Multicenter Neonatal Research Network
- Pharmacokinetics, Pharmacodynamics, and Safety of Methylprednisolone in Neonates on Cardiopulmonary Bypass
- Duke Resident Physician-Scientist Program- NHLBI
- Bridging the Gap to Enhance Clinical Research Program (BIGGER)
- PTN TO #41: Sildenafil II
- Investigating polypharmacy-related adverse events in critically ill children using electronic health records and simulated drug levels
- UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
- Center for Innovative TRIals in ChilDrEN and AdulTs (TRIDENT)
- 2/5 HEAL Consortium: Establishing Innovative Approaches for the HEALthy Brain and Child Development Study
- PTN TO#37 Obesity CNS PK Trial
- UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
- PTN TO# 35 Furosemide II
- PTN Task Order 25 SCAMP Modification
- PTN TO #25 SCAMP
- UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
- Echocardiogram to Diagnose Pulmonary Hypertension in Premature Infants
- PTN Task Order: Safety of Furosemide in Premature Infants
- PTN Task Order: CAFFEINE
- Comparative Effectiveness of Vesicoureteral Reflux Treatments in Children
- SOLI - Solithromycin Pediatric Development Program (Phase 2/3)- Labor & Sub Cost
- Growth Failure in Extremely Preterm Infants: Microbiomic and Metabolomic Analysis
- PTN TO#44 Baby Mercy Tape II (TAP03)
- Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia
- PTN TO #21- Pharmacokinetics of Multiple Dose Methadone in Children
- Linking Safety Practices to Adverse Events and Outcomes in Hospitalized Infants
- PTN TO 23-The Effect of Obesity on the Pharmacokinetics of Pantoprazole in Children
- PTN TO #34: Program Management Support
- PTN TO#14 (Mod #3) - Efficacy of sildenafil in premature infants with Pulmonary Hypertension
- PTN Task Order #13: Pharmacokinetics of Antistaphylococcal Antibiotics in Infants
- The Duke Multidisciplinary Training Program in Pediatric Lung Disease
- PTN Task Order 34 - Program Management Support
- Efficacy of Antiviral Suppression Therapy after Neonatal HSV Infection of the CNS
- PTN Task Order--Protocol Development III
- PTN Task Order #16: Pediatrix Safety Study
- PTN TO 22-Bronchopulmonary Dysplasia (BPD) and the Use of Diuretics in the NICU
- PTN Task Order #24: Protocol Development II
- PTN Task Order #14: Sildenafil study
- PHARMACOKINETICS OF ANTIMICROBIAL AGENTS IN HIGH RISK INFANTS
- Accelerating Adoption of Comparative Effectiveness Research in Premature Infants
- North Carolina Collaborative PPRU Network
- Best Pharmaceutical for Children Act (BPCA): Use of Meropenem in Infants